Skip to main content
. Author manuscript; available in PMC: 2020 Nov 6.
Published in final edited form as: Nitric Oxide. 2018 Oct 28;82:59–74. doi: 10.1016/j.niox.2018.10.006

Fig. 3.

Fig. 3.

Pharmacological activation of NO/cGMP every other day for 9 days causes chronic hyperalgesia that does not revert to baseline until days 13–15[120]. Thus, days after clearance of exogenous NO/cGMP activators, endogenous NO/cGMP signaling is upregulated and potentiates chronicity. Blocking sGC using ODQ restores baseline response on day 10. This migraine model is responsive to various anti-migraine drugs in human use.